Compare Stocks

Date Range: 

 OcugenAtara BiotherapeuticsMesoblastCortexymeCuris
SymbolNASDAQ:OCGNNASDAQ:ATRANASDAQ:MESONASDAQ:CRTXNASDAQ:CRIS
Price Information
Current Price$9.76$13.96$6.73$36.52$9.69
52 Week RangeBuyBuyHoldHoldBuy
MarketRank™
Overall Score1.01.41.41.61.3
Analysis Score1.33.43.23.13.5
Community Score3.32.83.12.62.6
Dividend Score0.00.00.00.00.0
Ownership Score0.00.00.02.50.0
Earnings & Valuation Score0.60.60.60.00.6
Analyst Ratings
Consensus RecommendationBuyBuyHoldHoldBuy
Consensus Price Target$8.38$35.88$14.55$50.00$14.60
% Upside from Price Target-14.19% downside156.98% upside116.20% upside36.91% upside50.67% upside
Trade Information
Market Cap$1.91 billion$1.11 billion$921.15 million$990.01 million$890.48 million
Beta3.562.653.710.953.29
Average Volume74,581,320923,315547,550281,4291,964,250
Sales & Book Value
Annual RevenueN/AN/A$32.16 millionN/A$10 million
Price / SalesN/AN/A27.15N/A88.68
CashflowN/AN/AN/AN/AN/A
Price / CashN/AN/AN/AN/AN/A
Book Value$0.21 per share$5.37 per share$4.70 per share$4.30 per share($1.02) per share
Price / BookN/AN/A1.43N/A-9.50
Profitability
Net Income$-20,240,000.00$-290,980,000.00$-77,940,000.00$-36,980,000.00$-32,140,000.00
EPS($1.48)($5.67)($0.74)($1.94)($0.86)
Trailing P/E RatioN/AN/AN/AN/AN/A
Forward P/E RatioN/AN/AN/AN/AN/A
P/E GrowthN/AN/AN/AN/AN/A
Net MarginsN/AN/A-591.00%N/A-279.33%
Return on Equity (ROE)-47.72%-94.86%-18.69%-37.78%N/A
Return on Assets (ROA)-30.78%-82.17%-13.85%-35.24%-81.32%
Dividend
Annual PayoutN/AN/AN/AN/AN/A
Dividend YieldN/AN/AN/AN/AN/A
Three-Year Dividend GrowthN/AN/AN/AN/AN/A
Payout RatioN/AN/AN/AN/AN/A
Years of Consecutive Dividend GrowthN/AN/AN/AN/AN/A
Debt
Debt-to-Equity Ratio0.13%N/A0.10%N/AN/A
Current Ratio4.78%9.41%1.32%8.71%3.10%
Quick Ratio4.78%9.41%1.32%8.71%3.10%
Ownership Information
Institutional Ownership Percentage8.53%N/A2.80%55.48%34.66%
Insider Ownership Percentage3.54%4.30%18.80%19.80%7.34%
Miscellaneous
Employees154801023728
Shares Outstanding188.17 million84.08 million129.74 million29.59 million91.52 million
Next Earnings Date8/13/2021 (Estimated)8/4/2021 (Estimated)5/26/2021 (Estimated)8/16/2021 (Estimated)5/12/2021 (Confirmed)
OptionableNot OptionableOptionableOptionableNot OptionableOptionable
SourceHeadline
Is Curis, Inc. (CRIS) Stock at the Top of the Biotechnology Industry? - InvestorsObserverIs Curis, Inc. (CRIS) Stock at the Top of the Biotechnology Industry? - InvestorsObserver
investorsobserver.com - May 11 at 10:54 AM
Chemocentryx’s future in doubt as avacopan foundation crumbles - VantageChemocentryx’s future in doubt as avacopan foundation crumbles - Vantage
evaluate.com - May 10 at 2:33 PM
Curis, Inc. to Post FY2022 Earnings of ($0.19) Per Share, Cantor Fitzgerald Forecasts (NASDAQ:CRIS)Curis, Inc. to Post FY2022 Earnings of ($0.19) Per Share, Cantor Fitzgerald Forecasts (NASDAQ:CRIS)
americanbankingnews.com - May 7 at 9:24 AM
Curis (CRIS) to Release Earnings on WednesdayCuris (CRIS) to Release Earnings on Wednesday
americanbankingnews.com - May 6 at 12:46 PM
Kymera Therapeutics Appoints Juliet Williams, PhD, as Senior Vice President, Head of Biology - StreetInsider.comKymera Therapeutics Appoints Juliet Williams, PhD, as Senior Vice President, Head of Biology - StreetInsider.com
streetinsider.com - May 5 at 6:23 PM
Curis to Release First Quarter 2021 Financial Results and Hold Conference Call on May 12, 2021 - Yahoo FinanceCuris to Release First Quarter 2021 Financial Results and Hold Conference Call on May 12, 2021 - Yahoo Finance
finance.yahoo.com - May 5 at 1:23 PM
Curis to Release First Quarter 2021 Financial Results and Hold Conference Call on May 12, 2021Curis to Release First Quarter 2021 Financial Results and Hold Conference Call on May 12, 2021
finance.yahoo.com - May 5 at 1:23 PM
Will Curis (CRIS) Report Negative Q1 Earnings? What You Should Know - Yahoo FinanceWill Curis (CRIS) Report Negative Q1 Earnings? What You Should Know - Yahoo Finance
finance.yahoo.com - May 4 at 6:23 PM
Will Curis (CRIS) Report Negative Q1 Earnings? What You Should KnowWill Curis (CRIS) Report Negative Q1 Earnings? What You Should Know
finance.yahoo.com - May 4 at 6:23 PM
Zacks: Brokerages Anticipate Curis, Inc. (NASDAQ:CRIS) Will Announce Earnings of -$0.09 Per ShareZacks: Brokerages Anticipate Curis, Inc. (NASDAQ:CRIS) Will Announce Earnings of -$0.09 Per Share
americanbankingnews.com - May 4 at 2:26 PM
Global Hodgkin Lymphoma Treatment Market by Type (Alocrest, ANK Program, Azacitidine, BMS-986016, BPX-501, Others), By Application (Hospital, Clinic, Research Center) And By Region (North America, Latin America, Europe, Asia Pacific and Middle East & Africa), Forecast To 2028 - Good News GumGlobal Hodgkin Lymphoma Treatment Market by Type (Alocrest, ANK Program, Azacitidine, BMS-986016, BPX-501, Others), By Application (Hospital, Clinic, Research Center) And By Region (North America, Latin America, Europe, Asia Pacific and Middle East & Africa), Forecast To 2028 - Good News Gum
goodnewsgum.com - May 4 at 1:23 PM
Sneak peek at McDonald’s Gospelfest 2021 - WPIX 11 New YorkSneak peek at McDonald’s Gospelfest 2021 - WPIX 11 New York
pix11.com - May 4 at 1:23 PM
Alliance Wealth Management Gro - GuruFocus.comAlliance Wealth Management Gro - GuruFocus.com
gurufocus.com - May 4 at 1:23 PM
Alliance Wealth Management Group Buys Invesco Fundamental High Yield Corporate Bond ETF, Curis ...Alliance Wealth Management Group Buys Invesco Fundamental High Yield Corporate Bond ETF, Curis ...
gurufocus.com - May 4 at 11:16 AM
Curis Stock Shows Every Sign Of Being Significantly Overvalued - Yahoo FinanceCuris Stock Shows Every Sign Of Being Significantly Overvalued - Yahoo Finance
finance.yahoo.com - May 3 at 10:21 PM
Hodgkin Lymphoma Treatment Market to Witness Huge Growth by 2026 | Cell Medica Limited, Cellular Biomedicine Group, Inc., Constellation Pharmaceuticals, Inc., Curis - Clark County BlogHodgkin Lymphoma Treatment Market to Witness Huge Growth by 2026 | Cell Medica Limited, Cellular Biomedicine Group, Inc., Constellation Pharmaceuticals, Inc., Curis - Clark County Blog
clarkcountyblog.com - May 3 at 12:21 PM
Short Interest in Curis, Inc. (NASDAQ:CRIS) Decreases By 27.2%Short Interest in Curis, Inc. (NASDAQ:CRIS) Decreases By 27.2%
americanbankingnews.com - May 2 at 11:54 AM
Histone Deacetylase 1 Market Research with COVID-19 | 4SC AG, Acetylon Pharmaceuticals, Inc., Chipscreen Biosciences Ltd, Curis, Inc. - Clark County BlogHistone Deacetylase 1 Market Research with COVID-19 | 4SC AG, Acetylon Pharmaceuticals, Inc., Chipscreen Biosciences Ltd, Curis, Inc. - Clark County Blog
clarkcountyblog.com - April 30 at 8:35 PM
Histone Deacetylase 2 Market Size Prognosticated to Perceive a Thriving Growth by 2026 interpreted by a new report | 4SC AG, Acetylon Pharmaceuticals, Inc., Chipscreen Biosciences Ltd, Curis, Inc. - Clark County BlogHistone Deacetylase 2 Market Size Prognosticated to Perceive a Thriving Growth by 2026 interpreted by a new report | 4SC AG, Acetylon Pharmaceuticals, Inc., Chipscreen Biosciences Ltd, Curis, Inc. - Clark County Blog
clarkcountyblog.com - April 29 at 11:45 PM
Hodgkin Lymphoma Treatment Market Booming Segments; Investors Seeking Growth | Curis, Incyte, Cell Medica – Jumbo News - Jumbo NewsHodgkin Lymphoma Treatment Market Booming Segments; Investors Seeking Growth | Curis, Incyte, Cell Medica – Jumbo News - Jumbo News
jumbonews.co.uk - April 28 at 2:38 PM
Track Magnets Market Size, Status, Global Demands and Top Manufacturers 2021 | 4SC AG, Acetylon Pharmaceuticals, Inc., Chipscreen Biosciences Ltd, Curis, Inc. - Clark County BlogTrack Magnets Market Size, Status, Global Demands and Top Manufacturers 2021 | 4SC AG, Acetylon Pharmaceuticals, Inc., Chipscreen Biosciences Ltd, Curis, Inc. - Clark County Blog
clarkcountyblog.com - April 28 at 2:38 PM
Apremilast Reagent Market to Witness Growth Acceleration by Top Key Players – 4SC AG, Acetylon Pharmaceuticals, Inc., Chipscreen Biosciences Ltd, Curis, Inc. - Clark County BlogApremilast Reagent Market to Witness Growth Acceleration by Top Key Players – 4SC AG, Acetylon Pharmaceuticals, Inc., Chipscreen Biosciences Ltd, Curis, Inc. - Clark County Blog
clarkcountyblog.com - April 28 at 2:38 PM
These numbers prove just how vibrant the Curis, Inc. (NASDAQ:CRIS) stock has beenThese numbers prove just how vibrant the Curis, Inc. (NASDAQ:CRIS) stock has been
stocksregister.com - April 28 at 9:38 AM
Curis, Inc. (NASDAQ:CRIS): Stock Forecast For 2021 Still Looks Hot With A 1.7% IncreaseCuris, Inc. (NASDAQ:CRIS): Stock Forecast For 2021 Still Looks Hot With A 1.7% Increase
marketingsentinel.com - April 28 at 12:02 AM
Hodgkin Lymphoma Treatment Market 2021 Size, Share Industry Trends, Growth, Development Status, Future Plans Analysis by 2027| Key Companies Analysis- Cell Medica Limited, Cellular Biomedicine Group, Inc., Constellation Pharmaceuticals, Inc., Curis, Inc., Faron Pharmaceuticals Oy, etc. - Clark County BlogHodgkin Lymphoma Treatment Market 2021 Size, Share Industry Trends, Growth, Development Status, Future Plans Analysis by 2027| Key Companies Analysis- Cell Medica Limited, Cellular Biomedicine Group, Inc., Constellation Pharmaceuticals, Inc., Curis, Inc., Faron Pharmaceuticals Oy, etc. - Clark County Blog
clarkcountyblog.com - April 27 at 8:58 AM
DateCompanyBrokerageAction
5/10/2021OcugenChardan CapitalLower Price Target
5/7/2021OcugenCantor FitzgeraldDowngrade
3/4/2021OcugenRoth CapitalBoost Price Target
2/4/2021OcugenHC WainwrightUpgrade
3/2/2021Atara BiotherapeuticsWilliam BlairReiterated Rating
3/2/2021Atara BiotherapeuticsCitigroupUpgrade
12/9/2020Atara BiotherapeuticsSmith Barney CitigroupDowngrade
12/9/2020Atara BiotherapeuticsCitigroup Inc. 3% Minimum Coupon Principal Protected Based Upon RussellDowngrade
12/7/2020Atara BiotherapeuticsStifel NicolausBoost Price Target
11/23/2020Atara BiotherapeuticsMizuhoBoost Price Target
9/14/2020Atara BiotherapeuticsCanaccord GenuityBoost Price Target
6/30/2020Atara BiotherapeuticsEvercore ISIInitiated Coverage
5/12/2020Atara BiotherapeuticsJPMorgan Chase & Co.Boost Price Target
12/10/2019Atara BiotherapeuticsCowenReiterated Rating
4/13/2021MesoblastMaxim GroupUpgrade
1/19/2021MesoblastJefferies Financial GroupDowngrade
10/22/2020MesoblastRoyal Bank of CanadaInitiated Coverage
5/28/2020MesoblastLADENBURG THALM/SH SHBoost Price Target
12/19/2019MesoblastDawson JamesInitiated Coverage
9/10/2019MesoblastOppenheimerSet Price Target
12/7/2020CortexymeBank of AmericaUpgrade
9/24/2020CortexymeLifesci CapitalReiterated Rating
6/3/2019CortexymeCredit Suisse GroupInitiated Coverage
6/3/2019CortexymeJMP SecuritiesInitiated Coverage
3/30/2021CurisB. RileyInitiated Coverage
3/17/2021CurisJonestradingBoost Price Target
7/29/2020CurisLaidlawInitiated Coverage
8/3/2018CurisSunTrust BanksLower Price Target
(Data available from 5/11/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.